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Background
The A2A adenosine receptor is a member of the G protein-
coupled receptor family. It is known to posses several
unique structural and functional features that differ from
established signaling paradigms. Recently, the exception-
ally long (>120 amino acids) C-terminus of the receptor
has raised interest for its capacity to act as a binding site
for several "accessory" proteins. In search for interaction
partners we identified a list of possible candidates via a
yeast two-hybrid system. From the identified potential
interaction partners we further investigated (i) ARNO/
cytohesin-2, a guanine nucleotide exchange factor for the
small G protein ARF6, and (ii) SAP102, ''synapse-associ-
ated protein of 102 kDa'', and their effects on the signal-
ing properties of the A2A receptor.
Methods and results
Cell-lines (HEK-293 and PC12) with inducible expression
of ARNO or its catalytic inactive mutant E156K, as well as
cell-lines expressing ARF6 or the dominant negative
mutant T27N were created. None of these proteins altered
the receptor expression, signaling via adenylyl cyclase
after activation or long-term de- and resensitization kinet-
ics in PC12 cells. On the other hand, ARF6 and its guanine
nucleotide exchange factor ARNO are recruited to the cell
membrane after agonist stimulation of the receptor,
where they seem to stabilize the receptor/G protein com-
plex. The mutant proteins are recruited to the membrane
in a similar way but do not stabilize the receptor/ G pro-
tein complex. SAP102, as its eponymous name suggests, is
located at synaptic sites and is known to recruit glutamate
receptors during different stages of the brain develop-
ment. The overexpression of SAP102 in mouse hippocam-
pal neurons showed no apparent effects on the receptor
signaling properties. However, the role of SAP102 as an
interaction partner may lie in the alteration of receptor
mobility. To visualize possible differences in A2A receptor
membrane diffusion we utilize a single-particle tracking
approach. Epitope-tagged receptors are labeled with
quantum dots and their trajectories are recorded under
various conditions. To further characterize the A2A recep-
tor interactome under more physiological conditions we
use a two-step proteomics approach combining the tan-
dem affinity purification method and 2D-nano-LC-MS/
MS. This requires the introduction of an epitope-tagged
version of the A2A receptor. After establishing the method
in heterologous expression systems we want to continue
with this approach in native mouse tissues. Therefore we
will generate transgenic mice expressing a tagged A2A
receptor.
from 15th Scientific Symposium of the Austrian Pharmacological Society (APHAR) Joint meeting with the Hungarian Society of Experimental and Clinical 
Pharmacology (MFT) and the Slovenian Pharmacological Society (SDF)
Graz, Austria. 19-21 November 2009
Published: 12 November 2009
BMC Pharmacology 2009, 9(Suppl 2):A32 doi:10.1186/1471-2210-9-S2-A32
<supplement> <title> <p>15th Scientific Symposium of the Austrian Pharmacological Society (APHAR)</p> </title> <editor>Andrea Laslop and Thomas Griesbacher</editor> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-9-S2-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2210-9-S2-info.pdf</url> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S2/A32
© 2009 Gsandtner et al; licensee BioMed Central Ltd. 